NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 1 நாளுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Orchasp Q2 FY27 Net Profit at ₹0.31 Cr; Auditors Issue Multiple Audit Qualifications
Orchasp reported standalone revenue from operations of ₹1.89 Cr (₹189.75 lakhs) for Q2 FY27, down from ₹7.54 Cr in Q2 FY26. Standalone net profit stood at ₹0.31 Cr (₹30.60 lakhs) compared to ₹0.21 Cr in the prior-year period. Independent auditors issued a qualified conclusion citing ₹68.25 Cr carrying value in a cancelled Portuguese subsidiary transferred without clear valuation, along with unpaid statutory dues and unconfirmed receivables exceeding 6 months. Receivables stood at ₹167.78 Cr as of September 30, 2026, against annual revenues of ~₹21 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுOrchasp approved its un-audited Q2 and H1 FY27 results, showing subdued operational revenue and persistent auditor qualifications over investments and receivables.
ஏன் இது முக்கியம்The company's reported receivables (₹167.78 Cr) exceed its entire net worth (₹122 Cr) and TTM revenue (₹16 Cr) by more than 10x, presenting extreme impairment and balance sheet recovery risks.
Q2 FY27 Revenue from Operations: ₹189.75 லட்சம்Q2 FY27 Net Profit: ₹30.60 லட்சம்வர்த்தக வசூலிக்கவேண்டியவை: ₹16,777.77 லட்சம்Carrying Value of Subsidary Investment Under Qualification: ₹6,825 லட்சம்Receivables to TTM Revenue Ratio: ~1048%
📅 குறுகிய காலம்Negative market sentiment is likely due to sharply lower revenues year-over-year and serious auditor qualifications regarding non-operational assets and unconfirmed receivables.
📈 நீண்ட காலம்Severe structural headwinds remain until the company cleans up legacy trade receivables, resolves statutory tax defaults, and successfully operationalizes the Orchasp Inc US entity.
⚠ அபாய எச்சரிக்கைகள்
Audit qualification on carrying value of ₹68.25 Cr in cancelled subsidiary
Trade receivables of ₹167.78 Cr are overdue >6 months without external confirmation
Non-payment of TDS and other statutory dues due to liquidity constraints
👀 கவனிக்க வேண்டியவை
Monitor whether the company initiates provisions for doubtful debts in ensuing quarters as indicated, and track RBI approval progress for the newly incorporated US subsidiary Orchasp Inc.
Orchasp Board Approves ₹7.11 Cr Preferential Issue via Loan Conversion to Promoter Group
Orchasp Limited's Board approved the conversion of an outstanding loan into equity by issuing up to 1.50 crore equity shares of face value ₹2 each at ₹4.74 per share (including a premium of ₹2.74), aggregating to ₹7.11 crore. The allotment is being made on a preferential basis to promoter group entity Wahtulmsylh Limgawlat, which will hold a 4.15% stake post-issuance. The transaction value represents approximately 19.2% of the company's current market cap of ₹37 crore. The issuance is subject to shareholder approval at the AGM scheduled for September 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is converting a ₹7.11 crore promoter group loan into 1.50 crore fresh equity shares at an issue price of ₹4.74 per share.
ஏன் இது முக்கியம்The conversion eliminates ₹7.11 crore in liabilities from the balance sheet and strengthens the net worth without cash outflow, priced above the current market price of ₹1.40.
Issue Size: ₹7.11 கோடிShares to be Issued: 1,50,00,000Issue Price per Share: ₹4.74Post-Issue Holding of Allottee: 4.15%Issue Size vs Market Cap: ~19.2%AGM Date: செப்டம்பர் 30, 2026
📅 குறுகிய காலம்Likely to be viewed constructively by the market due to debt conversion at ₹4.74 per share compared to current market prices.
📈 நீண்ட காலம்Reduces debt obligations and reinforces promoter group commitment, though long-term performance hinges on turning around core IT operating profitability.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of existing minority shareholders by 4.15%
Shareholder approval is pending at the AGM
👀 கவனிக்க வேண்டியவை
Track the voting outcome of the upcoming AGM on September 30, 2026, for shareholder approval, followed by stock exchange in-principle listing approvals.
Orchasp Limited Reports FY26 Net Profit of ₹1.05 Cr; Auditor Issues Qualified Opinion
Orchasp Limited returned to profitability in FY26, reporting a standalone net profit of ₹105.20 lakhs compared to a massive loss of ₹1,052.35 lakhs in FY25. However, the company's Q4 revenue dropped significantly to ₹161.26 lakhs from ₹700.96 lakhs year-on-year. A major concern for investors is the Auditor's Qualified Opinion, which highlights a ₹68.25 crore investment in a non-operational Portuguese subsidiary and the non-payment of statutory dues like TDS.
முக்கிய அம்சங்கள்
Company turned profitable in FY26 with a net profit of ₹105.20 lakhs vs a loss of ₹1,052.35 lakhs in FY25.Auditor issued a qualified opinion regarding the ₹6,825 lakh carrying value of a non-operational subsidiary facing cancellation of incorporation.Q4 revenue from operations saw a sharp decline to ₹161.26 lakhs compared to ₹700.96 lakhs in the same quarter last year.Auditors reported non-payment of Tax Deducted at Source (TDS) and other statutory dues up to March 31, 2026.Trade receivables and payables outstanding for over 6 months lack confirmation, making recoverability uncertain.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the auditor's qualified opinion and statutory defaults (TDS) are significant red flags. The uncertainty surrounding the ₹68.25 crore investment impairment could materially impact future book value.
Orchasp Receives ₹12.59 Crore GST Demand for Import of Services
Orchasp Limited has received a Spot Memo from the GST Audit authority in Hyderabad for the period 2020-21 to 2023-24. The memo alleges non-payment of GST on the import of services under the Reverse Charge Mechanism (RCM). The quantified tax demand stands at ₹12.59 Crores, excluding interest and penalties which are yet to be determined. The company is currently evaluating the legal and financial implications of this notice.
முக்கிய அம்சங்கள்
Tax demand of ₹12,58,59,446 (approx. ₹12.59 Crores) issued by the Commissioner of GST, Hyderabad.The audit covers a four-year period from financial year 2020-21 to 2023-24.Alleged violation involves non-payment of GST on Import of Services under Section 20 of the IGST Act.Interest and penalties are yet to be quantified and will be additional to the base tax amount.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the tax demand is significant and could impact the company's liquidity and profitability. Monitor for updates on whether the company contests the demand or makes a provision in its financial statements.
Orchasp's INDUSAYUSH Health Platform Approved for Apple App Store
Orchasp Limited has announced that its electronic health records (EHR) platform, INDUSAYUSH, was officially admitted to the Apple App Store on February 24, 2026. This milestone allows the company to distribute its digital health solution to a global iOS user base, enhancing its market reach. The approval follows the platform's development as a key digital asset for the company. Investors should note this as a positive step in the company's product scaling and digital health strategy.
முக்கிய அம்சங்கள்
INDUSAYUSH electronic health records platform admitted to Apple App Store on February 24, 2026The app is now available for global distribution to iOS users via the App StoreDisclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015The move enables the company to leverage Apple's ecosystem for user engagement and monetization
👀 கவனிக்க வேண்டியவை
Investors should monitor the adoption rates and user feedback of the INDUSAYUSH app to gauge its potential impact on future revenue. Watch for updates on the platform's monetization strategy in upcoming quarterly earnings calls.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Orchasp Ltd Approves Q3 Results with Qualified Audit Opinion and Major Board Reconstitution
Orchasp Limited has approved its unaudited financial results for the quarter ended December 31, 2025, which notably received a qualified opinion from statutory auditors. The company is undergoing a significant board transition with the appointment of two new directors, including the sister of the current MD & CFO as a Non-Executive Director. Simultaneously, three Independent Directors are scheduled to exit the board between February and March 2026 following the completion of their tenures. This has led to a full reconstitution of the Audit, Nomination, and Stakeholders Relationship committees.
முக்கிய அம்சங்கள்
Statutory auditors JMT & Associates issued a qualified opinion on the Q3 FY2025-26 financial results.Mr. Srinivasu Sunkara appointed as Independent Director for a 5-year term effective February 10, 2026.Ms. Sirisha Pattapurathi, sister of MD & CFO P. Chandra Sekhar, appointed as Non-Executive Non-Independent Director.Three Independent Directors (Ms. Ponnari Gottipati, Mr. Bade Srinivasa Reddy, and Mr. Sai Roopkumar Vegunta) to cease office by March 6, 2026.Board committees including Audit and Stakeholders Relationship reconstituted effective February 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution and specifically review the 'qualified opinion' in the financial statements to understand the auditor's concerns. The simultaneous exit of three independent directors and the appointment of a promoter-related director warrant close monitoring of corporate governance standards.
Orchasp Limited has announced a significant board reshuffle, appointing Mr. Srinivasu Sunkara as an Independent Director for a five-year term and Ms. Sirisha Pattapurathi as a Non-Executive Director. These appointments coincide with the upcoming departure of three Independent Directors between February and March 2026. Notably, the company's Q3 FY26 financial results were approved but received a qualified opinion from the statutory auditors, JMT & Associates. Investors should note that Ms. Pattapurathi is the sister of the current Managing Director and CFO.
முக்கிய அம்சங்கள்
Appointment of Mr. Srinivasu Sunkara as Independent Director for a 5-year term ending February 2031.Ms. Sirisha Pattapurathi appointed as Non-Executive Director; she is the sister of the MD & CFO.Three Independent Directors (Ms. Ponnari Gottipati, Mr. Bade Reddy, and Mr. Sai Vegunta) to exit by March 6, 2026.Statutory auditors issued a qualified opinion on the unaudited financial results for the quarter and nine months ended December 31, 2025.Board committees, including Audit and Nomination, were reconstituted effective February 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors should carefully review the specific reasons behind the auditor's qualified opinion in the Q3 results to assess financial transparency risks. Monitor how the significant turnover in independent directors affects the company's corporate governance standards.
Orchasp's INDUSAYUSH Health Platform Now Live on Google Play Store
Orchasp Limited has announced the successful admission of its electronic health records (EHR) platform, INDUSAYUSH, on the Google Play Store effective December 31, 2025. This launch represents a key milestone in the company's digital healthcare strategy, providing broader access to its services for Android users. The availability of the app is expected to facilitate user acquisition and enhance the visibility of the company's healthcare technology offerings. Investors should note this as a positive step toward scaling their digital product portfolio.
முக்கிய அம்சங்கள்
INDUSAYUSH electronic health records platform admitted to Google Play Store on December 31, 2025Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015The app is now publicly accessible for download, marking a transition from development to market availabilityMove aims to strengthen the company's footprint in the digital health and EHR management sector
👀 கவனிக்க வேண்டியவை
Investors should monitor the app's download growth and user reviews to gauge market adoption. It is also important to look for upcoming management commentary regarding the monetization plan for the INDUSAYUSH platform.
Orchasp Allots 2.68 Crore Equity Shares at Rs 3.20 to Settle Debt
Orchasp Limited has approved the allotment of 2,68,75,000 equity shares on a preferential basis at an issue price of Rs 3.20 per share. These shares are being issued to Mrs. P. Rajeswari, the legal heir of the company's former Chairman & CEO, Mr. P.C. Pantulu. The allotment serves to convert outstanding loan amounts into equity, effectively reducing the company's debt liabilities. While this move results in equity dilution, it improves the company's balance sheet by settling debt without cash outflow.
முக்கிய அம்சங்கள்
Allotment of 2,68,75,000 equity shares with a face value of Rs 2 each.Preferential allotment price set at Rs 3.20 per share.Shares issued to settle outstanding loan amounts of the late ex-Chairman & CEO.Total transaction value for debt-to-equity conversion is approximately Rs 8.6 crore.Board has authorized the Managing Director to proceed with listing and trading permissions.
👀 கவனிக்க வேண்டியவை
Investors should view the debt reduction as a positive for the company's financial health, though they should be mindful of the resulting equity dilution. Monitor the company's upcoming quarterly results to see the impact of reduced interest burdens.
Orchasp receives in-principle approval for equity share issue
Orchasp Limited has received in-principle approval from the NSE for issuing equity shares of ₹2 each under preferential terms. The approval is subject to the company fulfilling several conditions, including filing the listing application promptly and complying with regulations from SEBI, RBI, and MCA. The NSE has also advised Orchasp to strengthen internal controls to monitor trading by allottees and ensure compliance with SEBI (ICDR) Regulations. Investors should monitor the company's progress in fulfilling these conditions and ensure compliance with regulatory requirements.
முக்கிய அம்சங்கள்
In-principle approval for issue of Equity shares of Rs. 2/- eachCompliance with SEBI (LODR) Regulations, 2015Compliance with Companies Act, 1956 / Companies Act, 2013Company advised to strengthen internal controls before allotment of securities
👀 கவனிக்க வேண்டியவை
Investors should monitor Orchasp's compliance with the conditions set by NSE and SEBI. Watch for the filing of the listing application and adherence to regulatory guidelines.
Orchasp to Incorporate Wholly-Owned Subsidiary 'Orchasp Inc' in USA
Orchasp Limited is expanding its operations by incorporating a wholly-owned subsidiary named "Orchasp Inc" in the USA. This decision follows a board evaluation that found the cost of reviving the dormant Cybermate Infotek Limited Inc subsidiary to be higher than creating a new one. The new subsidiary will focus on marketing the indusayush health care platform and enabling the mobile app on android and ios playstore. The proposed share capital for Orchasp Inc is 10,000 shares at USD 1 each, totaling USD 10,000.
முக்கிய அம்சங்கள்
Incorporating a wholly-owned subsidiary in USA named “Orchasp Inc”.Proposed share capital of 10,000 Shares of USD 1 each.Total investment of USD 10,000 in the new subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should monitor the performance of the new subsidiary and its impact on Orchasp's overall revenue and profitability. Keep an eye on the adoption and market penetration of the indusayush platform in the US market.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
